Short stature and growth hormone deficiency in a subset of patients with Potocki–Lupski syndrome: Expanding the phenotype of PTLS. Issue 9 (13th July 2020)

• Record Type: Journal Article
• Authors: Franciskovich, Rachel; Soler‐Alfonso, Claudia; Neira‐Fresneda, Juanita; Lupski, James R.; McCann‐Crosby, Bonnie; Potocki, Lorraine
• Is Part Of: American journal of medical genetics. Volume 182:Issue 9(2020)
• Page Start: 2077
• Page End: 2084
• Publication Date: 2020-07-13
• Subjects: growth hormone -- hypoglycemia -- Potocki–Lupski syndrome -- short stature; Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.61741
• Languages: English
• ISSNs: 1552-4825

Abstract

Abstract: Potocki–Lupski Syndrome (PTLS, MIM 610883), or duplication of chromosome 17p11.2, is a clinically recognizable condition characterized by infantile hypotonia, failure to thrive, developmental delay, intellectual disability, and congenital anomalies. Short stature, classified as greater than two standard deviations below the mean, has not previously been considered a major feature of PTLS. Retrospective chart review on a cohort of 37 individuals with PTLS was performed to investigate the etiology of short stature. Relevant data included anthropometric measurements, insulin growth factor‐1 (IGF‐1), insulin‐like growth factor binding protein 3 (IGFBP‐3), growth hormone (GH) stimulation testing, blood glucose levels, brain MRI, and bone age. Approximately 25% (9/37) of individuals with PTLS had short stature. Growth hormone deficiency (GHD) was definitively identified in two individuals. These two PTLS patients with growth hormone deficiency, as well as three others with short stature and no documented GHD, received growth hormone and obtained improvement in linear growth. One individual was identified to have pituitary abnormalities on MRI and had complications of hypoglycemia due to unrecognized GHD. Individuals with PTLS can benefit from undergoing evaluation for GHD should they present with short stature or hypoglycemia. Early identification of GHD could facilitate potential therapeutic benefit for individuals with PTLS, including linear growth, musculoskeletal, and in cases of hypoglycemia, potentially cognitive development as well.